TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of participants with >12% and 200-mL increases in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bond strength of metal-ceramic systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in integrated AQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in healthcare use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prediction of liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PCSK9 levels at day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the receiver operating characteristic curve (AUC-ROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity, specificity, positive predictive value, and negative predictive value for predicting significant fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean elapsed time for bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall colon-cleansing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall colon MCC-remaining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemodynamic variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: basal forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nitric oxide dependent endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to meeting an exit criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients meeting one of the exit criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ordering rates of imaging studies and procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression-Free Survival (PFS-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Papillary blood flow (BF) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Parapapillary retinal flow decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Arterial and venous vessel diameter (VD) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Colonization with L. crispatus CTV-05
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of working hours lost due to sick leave
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma CRP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TLR4 adipose and placental expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ox-LDL-Ab levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain/discomfort during catheter placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: average number of attacks per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effort to restrict drinking to avoid medical problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binge frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC subjective score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional IKDC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reports of hormonal contraceptive use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reports of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Baseline anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oppositional defiant disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organizational functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of patients with 25(OH)D ≥50 nmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean 25(OH)D levels after 3 and 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annual treatment costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uterine contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the Western Ontario Rotator Cuff Index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of AHD narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 fall post-exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: median onset of improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective duration of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinician-reported severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary prevention of type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumen volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean neointimal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Discussion of spirituality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resistance rates to clarithromycin, metronidazole, and levofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of A2143G and A2144G point mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: grade ⩾3 dysphagia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean secretion weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sneezes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work performance (D-CAT)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean IPSS decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Qmax increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial plasma-TAG responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fentanyl blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical condition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: OCTT (Oxygen Consumption Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of UCP results that confidently exclude UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to remission
Endpoint domain: Mortality/survival
Primary endpoint: Depression-free days
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression to ACS
Endpoint domain: Mortality/survival
Primary endpoint: Break up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in scar appearance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Conjunctival moxifloxacin C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAF AUC(0-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: premature discontinuation of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of planned preventive consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of conventional consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients admitted without a lung-related diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Asthma control according to GINA criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DFT energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete remission of seborrhoeic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolic inflexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 12-h postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-reported adherence to medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinic attendance rate
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Improvement in epilepsy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of vaginal dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of vaginal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased blood urea nitrogen concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased serum bilirubin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinically important PHQ-9 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical health improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage reduction in total seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median percentage reduction in tonic-atonic seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in seizure severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiovascular recurrence
Endpoint domain: Mortality/survival
Primary endpoint: proportion of days with urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in social and family relations
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Enhancement of psychological functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: nocturnal polyuria index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: micturition/24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgency episodes/24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urge incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual function
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Improvement in bowel habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pressure recovery adjustment of AVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytokine response (TNF-alpha, IL-6, IL-10, IL1-ra)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in resistant AVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair growth promotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter pathogenic colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative rate of sustained CVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to absolute neutrophil recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in VQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death and new or recurrent acute coronary syndrome by 12 months
Endpoint domain: Mortality/survival
Primary endpoint: AUC(t(ss)) and C(max(ss))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete history taking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein concentration in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: aggressive behavior rebound effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum estrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: leukocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: gamma-glutamyl transferase (GGT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of brain activation in the auditory cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: knee flexion angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hamstring-quadriceps ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximum knee extension torques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: systolic arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SpO2 measured by pulse oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PFPT attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: patient reported outcome symptom bother scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of ST depressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative pain assessed by the need for analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from operation to return to normal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CARE scale scores assessing empathy and therapeutic relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients achieving optimal levels of HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving optimal levels of TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving combined lipid targets (LDL-C, HDL-C, TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reporting of mammography behaviours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reporting of Pap testing behaviours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intrauterine growth retardation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: FACT‐B4 physical well‐being subscores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Colour match scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative bleeding prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: PSTT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events causing early termination
Endpoint domain: Adverse events/effects
Primary endpoint: rate of major cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cosmetic result (Excellent-Good vs Fair-Poor)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of internalizing problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FPG ≤7 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA(1c) ≤7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma methotrexate pharmacokinetics (AUC(0‐t), C(max), time to C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methotrexate protein binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cholesterol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compliance with exercise protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical activity enjoyment scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intention to engage in exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WSRS score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of late reconnection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear levels at 1-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Test positivity for CAD detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: effort tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coronary reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Air leakage from the mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEEP improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median decline in HIV‐1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychomotor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraobserver reliability of lumbar intervertebral measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver reliability of lumbar intervertebral measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TT3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean improvement in ACQ‐6 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in annual exacerbation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive functioning (DSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for repeat insertions
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate postoperative symptoms (sore throat and dysphagia)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of C-reactive protein and AGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-birth-weight term infant delivery
Endpoint domain: Mortality/survival